期刊文献+

提升我国医药企业社会责任路径研究 被引量:3

Study on the Path of Promoting Social Responsibility of Pharmaceutical Corporate in China
下载PDF
导出
摘要 目的:为加强我国医药企业社会责任的监督和管理提供参考。方法:分析我国医药企业社会责任现状及美国、欧洲国家等的国际经验,提出我国医药企业社会责任提升路径。结果与结论:从2005年企业社会责任首次写入《中华人民共和国公司法》后,我国政府日益重视企业社会责任的落实,但我国医药企业社会责任尚处于起步阶段并落后于其他行业。美国通过制定完善的医药政策法规、非政府组织参与监管、建立完善的金融激励机制等多路径提升企业的社会责任;德国、英国等欧洲国家的政府部门在推动企业社会责任中扮演着重要的角色,同时,完善的公民社会的监督体系是企业社会责任的重要推动力。我国在提升医药企业社会责任时,应通过充分发挥政府的监督管理作用、加强社会公众的监督和管理作用、加强社会金融责任制度建设、提高医药企业责任意识等多路径,切实提高医药企业的社会责任意识。 OBJECTIVE: To provide reference for strengthening the supervision and management of responsibility of pharmaceutical corporates in China. METHODS: The status quo of social responsibility of pharmaceutical corporates in China were analyzed, and international experience of the United States, European countries and so on were analyzed. The ways to enhance the social responsibility of pharmaceutical corporates in China were proposed. RESULTS & CONCLUSIONS: Since the corporate social responsibility was first written into the People's Republic of China Company Law in 2005, the Chinese government has attached great importance to the implement of corporate social responsibility; however, the social responsibility of pharmaceutical corporates in China is still in the initial stage and lags behind other industries. The United States promotes corporate social responsibility through the formulation of perfect medical policies and regulations, non-governmental organizations participating in supervision, and the establishment of a sound financial incentive mechanism; Government in Germany, Britain and other European countries play an important role in promoting corporate social responsibility; at the same time, perfect supervision system of civil society is an important driving force to promote corporate social responsibility. When promoting the social responsibility of pharmaceutical corporates in China, it is necessary to improve the awareness of social responsibility of pharmaceutical enterprises through multiple paths, such as giving full play the supervision and management role of government, strengthening public supervision and management function, strengthening the system construction of social financial responsibility, improving the awareness of responsibility of pharmaceutical corporates.
作者 沈茜
出处 《中国药房》 CAS 北大核心 2018年第1期4-8,共5页 China Pharmacy
基金 全国食品药品职业教育教学指导委员会课题(No.食药行指委[2017]14号-SYHZW201732) 浙江省教育厅高校访问工程师"校企合作项目"(No.FG2017004) 浙江省食品药品监督管理与产业发展研究会课题(No.ZYH2016009)
关键词 医药企业 社会责任 提升路径 国际经验 Pharmaceutical corporate Social responsibility Promoting path International experience
  • 相关文献

参考文献4

二级参考文献63

  • 1许俊才,方宁涛.美国食品药品监督管理局百年发展历程带给我国药品监管体系的启示[J].世界临床药物,2008(7):434-437. 被引量:6
  • 2陈俊,徐鹤定,王祖承.美国食品与药品管理局(FDA)介绍[J].国外医学(精神病学分册),2005,32(1):22-25. 被引量:5
  • 3郭薇.制药业如何面对减排大考?[N].中国环境报,2011-01-06(1).
  • 4Carroll AB. A three-dimensional conceptual model of cor- porate social performance[J]. Academy of Management Re- view, 1979, 4(4): 497.
  • 5Freeman RE. Strategic Management: A Stakeholder Appr- oach[M]. Boston: Cambridge University Press, 2010: 24- 28.
  • 6Snider J, Hill RP, Martin D. Corporate social responsibil- ity in the 21st century: a view from the world' s most suc- cessful firms[J]. Journal of Business Ethics, 2003,48 (2) : 175.
  • 7Margaret MB. Ownership and Control: Rethinking Corpo- rate Governance for the Twenty-first Century[M]. Wash- ington: Brookings Institution Press, 1995: 191-192.
  • 8张飞,徐炜.国外企业社会责任实施现状——以美国、英国、日本为例[R].重庆:中国企业改革发展三十年理论与实践研讨会暨中国企业管理研究会2008年年会,2008.
  • 9Ramchander S, Schwebach R G, Staking K I M. The informa- tional relevance of corporate social responsibility:evidence from DS400 index reconstitutions [J]. Strategic Management Journal,2012,33(3) :303-314.
  • 10Sparkes R,Cowton C J. The mathring of socially responsible investment: A review of the developing link with corporate social responsibility [J].Journal of Business Ethics, 2004,52 (1) :45-57.

共引文献46

同被引文献12

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部